Medicago prices overnight offering

Medicago (TSX:MDG) has carried out an overnight marketed offering and agreed to sell up to 34,117,600 units at a price of 51 cents a unit to raised $17.4 million. Each unit is comprised of one common share and one-quarter of a warrant, with each whole warrant exercisable to purchase another common share for 75 cents [...]

Medicago lowers warrant exercise price

The Toronto Stock Exchange has conditionally approved a reduction of the exercise price of Medicago (TSX:MDG) warrants issued in November, 2009 to 43 cents from $1. The warrants expire on Nov. 26, 2010. There are 8,050,000 outstanding, including 53,888 warrants held by Medicago insiders, which will remain at the original exercise price of $1. Proceeds [...]

Medicago offers $7 million of units

Medicago (TSX:MDG) has entered into an agency agreement and carried out an overnight marketed offering to sell up to 17,283,952 units at a price of 40.5 cents each in order to finance its $7.5 million share of a new U.S. pandemic vaccine plant that includes a grant from an arm of the U.S. Department of [...]

Medicago in funding talks for U.S. vaccine plant

Medicago (TSX:MDG) has begun negotiating final terms and conditions with the U.S. Defense Advanced Research Projects Agency (DARPA) for a financing package to build a scalable plant to make plant-expressed, virus-like particles (VLP) vaccines. Medicago submitted its proposal for the plant in March, 2010.  ”Our proposal being selected by DARPA for potential funding demonstrates our [...]

Medicago in vaccine MOU in Indonesia

Medicago (TSX:MDG) has signed a memorandum of understanding with Indonesia’s PT Bio Farma to develop select vaccine targets of mutual interest, with the final goal of establishing a partnership to build a Medicago plant-based manufacturing facility in the country. “This agreement confirms the suitability of our technology to support vaccine development in countries where manufacturing [...]

Medicago to begin trading on TSX tomorrow

Medicago (TSX-V:MDG) has received final approval to graduate to the TSX from the TSX Venture Exchange at the start of trading tomorrow, using the same stock symbol. The company also entered into standby equity distribution agreement to sell up to $10 million of new common shares in tranches to YA Global Master SPV, a fund managed by [...]

Medicago in vaccine MOU in Japan

Medicago (TSX-V: MDG) has signed a memorandum of understanding with Japan’s NITT Partners to discuss and negotiate an agreement to commercialize Medicago’s pandemic and seasonal influenza VLP-based vaccines in Japan and other territories. For several years, NITT Partners has been the government-approved technology transfer/licensing organization to license-in state of the art technologies. Under the terms [...]

Medicago to present at WHO meeting

Medicago (TSX:MDG) will present its Phase 1 clinical findings of the first plant-made influenza vaccine to be tested in humans at a meeting this week of the World Health Organization, evaluating pandemic influenza prototype vaccines in clinical trials. “It is a privilege to be among a select group of leading vaccine companies invited to present [...]

Waiting on Medicago trial results

In a New Idea of Interest report on Medicago (TSX-V:MDG), Dundee Securities said that if Phase 1 results for its lead H5N1 avian vaccine are positive in December, the company could “establish a leading position in the global effort to find a superior vaccine-production technology.” Analyst David Martin rates the stock “buy (speculative risk)” but [...]